Translating Neuroimmunological Mechanisms into Clinically Effective
Neurodegenerative Targeting Therapeutics
More and more pharma and biotech companies are investing in research focused on neuroimmunology and neuroinflammation’s relation to neurodegenerative diseases in the challenge to develop clinically effective therapeutics.
The 2nd Neuroimmunology Drug Development Summit’s agenda has specifically designed alongside neuroimmunology experts from the likes of Denali, AbbVie and Biogen to help these drug developers to overcome their translational challenges and successfully translate their drug candidates into the clinic.
Immerse yourself in the field’s cutting-edge scientific advances and take this unrivaled opportunity to join over 23 expert industry speakers and over 80 drug developers from the neuroimmunological community for over 7 hours of dedicated networking time and 2 deep-dive workshops.
To find out more and view the full speaker line-up, download the full event guide.
23 World-Class Speakers Including:
Director, Center for Translational Research in Neurodegenerative Disease & the Parkinson’s Foundation Research Center
The University of Florida College of Medicine
Chief Science Officer
Third Rock Ventures
Chief Medical Officer
Chief Executive Officer & President
|“Teriffic meeting and glad to have it on my radar” - Brett Adams, Vice President, Magnolia Neurosciences|
|"Very focused meeting, that accomplished a lot in two days. The presentations were high quality and organised into interesting sessions" - Sally Ishizaka, Senior Director, Eisai|
|'Excellent meeting! I learned a lot' - Gayathri Ramaswamy, Associate Director, Biogen|